Orion Corporation – AGM 6 May 2020
In general, Orion Corporation ("Orion") is in compliance with the Finnish regulations relating to the organisation and procedures of the Annual General Meeting.
Under ITEM 10 the board of directors seeks approval of the Company's executive remuneration policy. ECGS notes that, following the entry into force of the EU Shareholders'Rights Directive (SRD II), this is the first time that Orion's puts its executive remuneration policy to a vote. In general, ECGS considers the overall level of transparency of the policy to be below Finnish standards. ECGS furthermore notes that the performance period of the LTI varies between 1 and 3 year(s) and it does NOT consider the performance periods of 1 and 2 year(s) sufficiently long enough. In view of the above concerns, ECGS recommends to vote OPPOSE.
Orion and its subsidiaries develop and manufacture pharmaceuticals, active pharmaceutical ingredients and diagnostic tests that are marketed globally. Co. and its subsidiaries have two segments: Pharmaceuticals and Diagnostics. The Pharmaceuticals business develops, manufactures and markets pharmaceuticals and active pharmaceutical ingredients. The Pharmaceuticals business portfolio includes Co.'s Stalevo® (carbidopa, levodopa and entacapone) and Comtess®/Comtan® (entacapone) Parkinson's drugs. The Diagnostics business develops, manufactures and markets diagnostic tests.
Founded in 1995, Proxinvest is an independent proxy firm supporting the engagement and proxy analysis processes of investors. Proxinvest mission is to analyse corporate governance practices and resolutions proposed at general meetings of listed firms.
Proxinvest main services are :
- Proxy reports
- Definition and monitoring of client customized voting guidelines
- Corporate Governance Data and Rating
- Thematic research
- Engagement support
Proxinvest has been a pioneer and champion of good corporate governance and has grown into a recognised expert in the field.
Proxinvest is independently-owned and only works for investors : Proxinvest does not provide consulting services to the companies it covers, mitigating related risks to its clients and ensuring the independence of our analysis. As a result Proxinvest is able to take a robust, independent, engaged and unconflicted view of the companies in which our clients invest.
As Managing Partner of Expert Corprate Governance Service Ltd (ECGS), Proxinvest has built a large network of corporate governance experts to support clients in corporate governance analysis worldwide.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.